list incomplete help expanding
drugs medicines withdrawn commercial markets risks patients also commercial reasons lack demand relatively high production costs risks harms reason withdrawal usually prompted unexpected adverse effects detected phase clinical trials made apparent postmarketing surveillance data collected wider community longer periods time
list limited drugs ever approved lumiracoxib rimonabant tolrestat ximelagatran ximelidine example approved marketed europe approved marketing side effects became clear developers pulled market drugs list never approved marketing europe



contents


significant withdrawals
also
references
external links



significant withdrawalsedit


drug name
withdrawn
country
remarks


adderall
2005
canada
risk stroke1 later lifted death rate among taking adderall determined greater taking adderall


alatrofloxacin
2006
worldwide
liver toxicity serious liver injury leading liver transplant death2


alclofenac
1979

vasculitis rash3


alpidem ananxyl
1995
worldwide
approved withdrawn france 19944 rest market 1995 rare serious hepatotoxicity35


alosetron lotronex
2000

serious gastrointestinal adverse events ischemic colitis severe constipation2 reintroduced 2002 restricted basiscitation needed


althesin alphaxolone amineptine alphadolone
1984
france germany
anaphylaxis3


amineptine survector
1999
france
hepatotoxicity dermatological side effects abuse potential6 reason


aminopyrine
1999
france thailand
risk agranulocytosis severe acne3


amobarbital
1980
norway
risk overdose3


amoproxan
1970
france
dermatologic ophthalmic toxicity3


anagestone acetate
1969
germany
animal carcinogenicity3


antrafenine
1984
france
unspecific experimental toxicity3


aprotinin trasylol
2008

increased risk death2


ardeparin normiflo
2001

reasons safety efficacy7


astemizole hismanal
1999
malaysia multiple nonspecified markets
fatal arrhythmia23


azaribine
1976

thromboembolism3


bendazac
1993
spain
hepatotoxicity3


benoxaprofen
1982
germany spain
liver kidney failure gastrointestinal bleeding ulcers23


benzarone
1992
germany
hepatitis3


benziodarone
1964
france
jaundice3


betaethoxylacetanilanide
1986
germany
renal toxicity animal carcinogenicity3


bezitramide
2004
netherlands
risk fatal overdose8


bithionol
1967

dermatologic toxicity3


broazolam
1989

animal carcinogenicity3


bromfenac
1998

severe hepatitis liver failure requiring transplantation2


bucetin
1986
germany
kidney damage3


buformin
1978
germany
metabolic toxicity3


bunamiodyl
1963
canada
nephropathy9


butamben efocainebutoforme
1964

dermatologic toxicity psychiatric reactions3


canrenone
1986
germany
animal carcinogenicity3


cerivastatin baycol lipobay
2001

risk rhabdomyolysis2


chlormadinone chlormenadione
1970

animal carcinogenicity3


chlormezanone trancopal
1996
european union south africa japan
hepatotoxicity stevenjohnson syndrome


chlorphentermine
1969
germany
cardiovascular toxicity3


cianidanol
1985
france germany spain sweden
hemolytic anemia3


cinepazide
1988
spain
agranulocytosis1011


cisapride propulsid
2000

risk fatal cardiac arrhythmias2


clioquinol
1973
france germany
neurotoxicity3


clobutinol
2007
germany
ventricular arrhythmia qtprolongation12


cloforex
1969
germany
cardiovascular toxicity3


clomacron
1982

hepatotoxicity3


clometacin
1987
france
hepatotoxicity3


coproxamol distalgesic
2004

risk overdose


cyclobarbital
1980
norway
risk overdose3


cyclofenil
1987
france
hepatotoxicity3


dantron
1963
canada
mutagenic13 withdrawn general permitted terminal patients


dexfenfluramine
1997
european union
cardiotoxic3


propoxyphene darvocetdarvon
2010
worldwide
increased risk heart attacks stroke14


diacetoxydiphenolisatin
1971
australia
hepatotoxicity3


diethylstilbestrol
1970s

carcinogen


difemerine
1986
germany
multiorgan toxicities3


dihydrostreptomycin
1970

neuropsychiatric reaction3


dilevalol
1990

hepatotoxicity3


dimazole diamthazole
1972
france
neuropsychiatric reaction3


dimethylamylamine dmaa
1983

voluntarily withdrawn market lily1512 reintroduced dietary supplement 20061513 2013 started work cardiovascular problems16


dinoprostone
1990

uterine hypotonus fetal distress3


dipyronemetamizole
1975
others
agranulocytosis anaphylactic reactions3


dithiazanine iodide
1964
france
cardiovascular metabolic reaction3


dofetilide
2004
germany
drug interactions prolonged qt12


drotrecogin alfa xigris
2011
worldwide
lack efficacy shown prowessshock study171819


ebrotidine
1998
spain
hepatotoxicity3


efalizumab raptiva
2009
germany
withdrawn increased risk progressive multifocal leukoencephalopathy12


encainide
1991

ventricular arrhythmias23


ethyl carbamate
1963
canada
carcinogenicity20


etretinate
1989
france
withdrawn 1999 risk birth defects23


exifone
1989
france
hepatotoxicity3


fenphen popular combination fenfluramine phentermine
1997

cardiotoxicity


fenclofenac
1984

cutaneous reactions animal carcinogenicity3


fenclozic acid
1970

hepatotoxicity3


fenfluramine
1997
european union india south africa others
cardiac valvular disease pulmonary hypertension cardiac fibrosis321


fenoterol
1990
zealand
asthma mortality3


feprazone
1984
germany
cutaneous reaction multiorgan toxicity3


fipexide
1991
france
hepatotoxicity3


flosequinan manoplax
1993

increased mortality higher doses increased hospitalizations23


flunitrazepam
1991
france
abuse3


gatifloxacin
2006

increased risk dysglycemia2


gemtuzumab ozogamicin mylotarg
2010

improvement clinical benefit risk death2


glafenine
1984
france germany
anaphylaxis3


grepafloxacin raxar
1999
withdrawn germany others
cardiac repolarization interval prolongation2


hydromorphone palladone extended release version
2005

high risk accidental overdose extended release version palladone administered alcohol standard hydromorphone sold world including


ibufenac
1968

hepatotoxicity jaundice3


indalpine
1985
france
agranulocytosis3


indoprofen
1983
germany spain
animal carcinogenicity gastrointestinal toxicity3


iodinated casein strophantin
1964

metabolic reaction3


iproniazid
1964
canada
interactions food products containing tyrosine22


isaxonine phosphate
1984
france
hepatotoxicity3


isoxicam
1983
france germany spain others
stevens johnson syndrome3


kava kava
2002
germany
hepatotoxicity12


ketorolac
1993
france germany others
hemorrhage renal failure3


ltryptophan
1989
germany
eosinophilic myalgia syndrome3 still sold


levamisole ergamisol
1999

still used veterinary drug human antihelminthic many markets listed list essential medicines humans used treat melanoma withdrawn agranulocytosis232425


levomethadyl acetate
2003

cardiac arrhythmias cardiac arrest2


lumiracoxib prexige
2007–2008
worldwide
liver damage


lysergic acid diethylamide
1950s–1960s

marketed psychiatric drug withdrawn became widely used recreationally illegal world


mebanazine
1975

hepatotoxicity drug intereaction3


methandrostenolone
1982
france germany others
offlabel abuse3


methapyrilene
1979
germany
animal carcinogenicity3


methaqualone
1984
south africa 1971 india 1984 united nations 1971–1988
withdrawn risk addiction overdose2627


metipranolol
1990
others
uveitis3


metofoline
1965

unspecific experimental toxicity3


mibefradil
1998
european union malaysia others
fatal arrhythmia drug interactions23


minaprine
1996
france
convulsions3


moxisylyte
1993
france
necrotic hepatitis3


muzolimine
1987
france germany european union
polyneuropathy3


natalizumab tysabri
2005–2006

voluntarily withdrawn market risk progressive multifocal leukoencephalopathy returned market july 2006


nefazodone
2007
canada others
branded version withdrawn originator several countries 2007 hepatotoxicity generic versions available28


nialamide
1974

hepatotoxicity drug intereaction3


nikethamide
1988
multiple markets
stimulation3


nitrefazole
1984
germany
hepatic hematologic toxicity3


nomifensine
1981–1986
france germany spain others
hemolytic anemia hepatotoxicity serious hypersensitive reactions23


oxeladin
1976
canada 1976
carcinogenicity29


oxyphenbutazone
1984–1985
germany france canada
bone marrow suppression stevens–johnson syndrome33031


oxyphenisatin phenisatin

australia france germany
hepatotoxicity3


ozogamicin
2010

improvement clinical benefit risk death venoocclusive disease2


pemoline cylert
1997
canada
withdrawn 2005 hepatotoxicity32 reasonhepatotoxicity3


pentobarbital
1980
norway
risk fatal overdose3


pentylenetetrazol
1982

withdrawn inability produce effective convulsive therapy causing seizures


pergolide permax
2007

risk heart valve damage2


perhexilene
1985
spain
neurologic hepatic toxicity3


phenacetin
1975
canada
ingredient tablet withdrawn risk cancer kidney disease33 germany denmark others reason nephropathy3


phenformin buformin
1977
france germany
severe lactic acidosis3


phenolphthalein
1997

carcinogenicity34


phenoxypropazine
1966

hepatotoxicity drug intereaction3


phenylbutazone
1985
germany
offlabel abuse hematologic toxicity3


phenylpropanolaminepropagest dexatrim
2000
canada
hemorrhagic stroke3536


pifoxime pixifenide
1976
france
neuropsychiatric reaction3


pirprofen
1990
france germany spain
liver toxicity310223


prenylamine
1988
canada france germany others
cardiac arrythmia37 death3


proglumide
1989
germany
respiratory reaction3


pronethalol
1965

animal carcinogenicity3


propanidid
1983

allergy3


proxibarbal
1998
spain france italy portugal turkey
immunoallergic thrombocytopenia3


pyrovalerone
1979
france
abuse3


rapacuronium raplon
2001
multiple markets
withdrawn many countries risk fatal bronchospasm2


remoxipride
1993
others
aplastic anemia3


rimonabant acomplia
2008
worldwide
risk severe depression suicide12


rofecoxib vioxx
2004
worldwide
withdrawn merck risk myocardial infarction stroke2


rosiglitazone avandia
2010
europe
risk heart attacks death drug continues available


secobarbital

france norway others
risk overdose3


sertindole
1998
european union
arrhythmia sudden cardiac death338


sibutramine reductilmeridia
2010
australia39 canada40 china41 european union eu42 hong kong43 india44 mexico zealand45 philippines46 thailand47 united kingdom48 united states49
increased risk heart attack stroke2


sitaxentan
2010
germany
hepatotoxicity12


sorivudine
1993
japan
drug interaction deaths50


sparfloxacin
2001

prolongation phototoxicity2


sulfacarbamide
1988
germany
dermatologic hematologic hepatic reactions3


sulfamethoxydiazine
1988
germany
unknown3


sulfamethoxypyridazine
1986

dermatologic hematologic reactions3


suloctidyl
1985
germany france spain
hepatotoxicity3


suprofen
1986–1987
spain
kidney damage23


tegaserod zelnorm
2007

risk heart attack stroke unstable angina2 available restricted access program april 2008


temafloxacin
1992
germany others
blood sugar hemolytic anemia kidney liver dysfunction allergic reactions23


temafloxacin
1992

allergic reactions cases hemolytic anemia leading three patient deaths2


temazepam restoril euhypnos normison remestan tenox norkotral
1999
sweden norway
diversion abuse relatively high rate overdose deaths comparison drugs group drug continues available world including strict controls


terfenadine seldane triludan
1997–1998
france south africa oman others
prolonged interval ventricular tachycardia23


terodiline micturin
1991
germany spain others
prolonged interval ventricular tachycardia arrhythmia3


tetrazepam
2013
european union
serious cutaneous reactions51


thalidomide
1961
germany
withdrawn risk teratogenicity52 returned market leprosy multiple myeloma orphan drug rules


thenalidine
1960
canada
neutropenia353


thiobutabarbitone
1993
germany
renal insufficiency3


thioridazine melleril
2005
germany
withdrawn worldwide severe cardiac arrhythmias5455


ticrynafentienilic acid
1980
germany france others
liver toxicity death3


tolcapone tasmar
1998
european union canada australia
hepatotoxicity3


tolrestat alredase
1996
argentina canada italy others
severe hepatotoxicity3


triacetyldiphenolisatin
1971
australia
hepatotoxicity3


triazolam
1991
france netherlands finland argentina others
psychiatric adverse drug reactions amnesia356


triparanol
1962
france
cataracts alopecia ichthyosis3


troglitazone rezulin
2000
germany
hepatotoxicity2


trovafloxacin trovan
1999–2001
european union
withdrawn risk liver failure23


valdecoxib bextra
2004

risk heart attack stroke2


vincamine
1987
germany
hematologic toxicity3


xenazoic acid
1965
france
hepatotoxicity3


ximelagatran exanta
2006
germany
hepatotoxicity12


zimelidine
1983
worldwide
risk guillain–barré syndrome hypersensitivity reaction hepatotoxicity35758 banned worldwide59


zomepirac
1983
germany spain
anaphylactic reactions nonfatal allergic reactions renal failure23


alsoedit

adverse drug reaction
adverse events
european medicines agency
food drug administration

referencesedit



branch government canada health canada public affairs consultation communications health canada home page retrieved november 2016
qureshi seoanevazquez rodriguezmonguio stevenson szeinbach july 2011 market withdrawal molecular entities approved united states 1980 2009 pharmacoepidemiology drug safety 772–7 doi101002pds2155 pmid 21574210
fung thornton mybeck hornbuckle muniz january 2001 evaluation characteristics safety withdrawal prescription drugs worldwide pharmaceutical markets1960 1999 therapeutic innovation regulatory science 293–317 doi101177009286150103500134
drug information 1994 page retrieved november 2016
berson 2001 toxicity alpidem peripheral benzodiazepine receptor ligand zolpidem hepatocytes role mitochondrial permeability transition metabolic activation pharmacol ther 2992793–800
drugbank amineptine retrieved september 2013
response citizen request ardeparin
drugbank bezitramide retrieved september 2013
drugbank bunamiodyl retrieved september 2013
consolidated list products whose consumption andor sale banned withdrawn severely restricted approved governments twelfth issue pharmaceuticals united nations york 2005
department economic social affairs united nations secretariat consolidated list products whose consumption andor sale banned withdrawn severely restricted approved governments twelfth issue pharmaceuticals united nations york 2005
schubertzsilavecz manfred 2011 arzneimittelrücknahmen rückrufe rückblick pharmazeutische zeitung german retrieved september 2013
drugbank dantron retrieved september 2013
press announcements xanodyne agrees withdraw propoxyphene market retrieved november 2016
john lammie report department defense dimethylamylamine dmaa safety review panel archived 20140119 wayback machine june 2013
stimulant potentially dangerous health warns retrieved january 2014
drotrecogin alfa activated adults septic shock engl 2012 3662055–2064 2012 doi101056nejmoa1202290
xigris drotrecogin alfa activated withdrawn lack efficacy press release london european medicines agency october 2011 archived original october 2011 retrieved october 2011
httpwwwbusinessweekcomnews20111025lillypullsxigrisoffmarketsaftersepsisdrugfailsstudyhtml
drugbank ethyl carbamate retrieved september 2013
drugbank fenfluramine retrieved september 2013
drugbank iproniazid retrieved september 2013
centers disease control prevention december 2009 agranulocytosis associated cocaine four states march 2008 november 2009 morb mortal wkly 1381–5 pmid 20019655
nancy donald legatt robert turner february 2009 agranulocytosis consumption cocaine adulterated levamisole annals internal medicine 287–289 doi10732600034819150420090217000102 pmid 19153405 retrieved 20091007
kinzie erik april 2009 levamisole found patients using cocaine annals emergency medicine 546–7 doi101016jannemergmed200810017 pmid 19303517 retrieved 20090818
central drugs standard control organization drugs banned india ministry health family welfare government india archived original february 2015 retrieved september 2013
drug effects methaqualone south african police service retrieved september 2013
cosgrovemather bootie december 2007 antidepressant taken market news retrieved september 2013
drugbank oxeladin retrieved september 2013
drugbank oxyphenbutazone retrieved september 2013
biron 1986 withdrawal oxyphenbutazone phenylbutazone cmaj canadian medical association journal 1119–20 1491052 pmid 3697857
drugbank pemoline retrieved september 2013
drugbank phenacetin retrieved september 2013
wysowski diane 2005 adverse drug event surveillance drug withdrawals united states 1969–2002 importance reporting suspected reactions archives internal medicine 1363–9 doi101001archinte165121363 pmid 15983284 first2 missing last2 authors list help
commissioner office safety alerts human medical products phenylpropanolamine hydrochloride retrieved november 2016
drugbank phenylpropanolamine retrieved september 2013
drugbank prenylamine retrieved september 2013
drugbank sertindole retrieved september 2013
sibutramine brand name reductil information australia abbott laboratories 2010 archived original 20101014 retrieved 20101008
health canada endorsed important safety information meridia sibutramine hydrochloride monohydrate subject voluntary withdrawal meridia sibutramine capsules canadian market
notification termination production sale usage sibutramine preparations active pharmaceutical ingredient sdagov peoples republic china october 2010 retrieved 20110521
german sibutraminvertrieb europäischen union ausgesetzt abbott laboratories germany press release 20100121 retrieved 20100127
deregistration pharmaceutical products containing sibutramine press release infogov hong kong november 2010 retrieved 20101108
banned medicines press release ministry health family welfare february 2011 retrieved 20110315
withdrawal sibutramine reductil zealand press release medsafe zealand october 2010 archived original october 2012 retrieved 20121106
warns online sellers banned slimming pills january 2014 retrieved february 2014
thai reveals voluntary withdrawal sibutramine thai market press release food drug administration thailand october 2010 retrieved 20101222
obesity drug sibutramine suspended news 20100122 retrieved 20100122
rockoff jonathan dooren jennifer corbett october 2010 abbott pulls diet drug meridia shelves wall street journal retrieved october 2010
gurdon japan bans shingles drug deaths 1994309627
paar müllerjakic ruhen zulassung tetrazepam haltiger arzneimittel german sanofiaventis deutschland gmbh retrieved september 2013
luippold gerd 2006 renaissance conterganwirkstoffs pharmazeutische zeitung german retrieved september 2013
drugbank thenalidine retrieved september 2013
purhonen koponen tiihonen tanskanen november 2012 outcome patients market withdrawal thioridazine retrospective analysis nationwide cohort pharmacoepidemiology drug safety 1227–1231 doi101002pds3346 pmid 22941581
shared care protocol thioridazine lothian joint formulary march 2012
drugbank triazolam retrieved september 2013
fagius guillain–barré syndrome following zimeldine treatment neurol neurosurg psychiatry 1985 jan481659
pubchem record says withdrawn 1983
drugbank zimelidine retrieved september 2013



external linksedit

cder report nation 2005 list withdrawals 2005






retrieved httpsenwikipediaorgwindexphptitlelistofwithdrawndrugsoldid818412879 categories withdrawn drugsdrugrelated listsmedicine timelineshidden categories webarchive template wayback linkscs1 errors missing author editorarticles germanlanguage external linksincomplete lists july 2015all articles unsourced statementsarticles unsourced statements january 2014
